The genetic testing pioneer lost $500 million in value after reporting fiscal Q3 operating results.
News & Analysis: Myriad Genetics
These stocks struggled on a mixed day on Wall Street.
MYGN earnings call for the period ending March 31, 2019.
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
Quarterly earnings from around the industry suggested the epic growth opportunity isn't slowing down anytime soon.
MYGN earnings call for the period ending December 31, 2018
The genetic testing pioneer announced fiscal first-quarter 2019 results, but had to reduce full-year revenue guidance.
Three short years ago, Myriad Genetics was the undisputed leader of the genetic testing industry. A persistent competitor just challenged the diagnostic company -- and a second one is nipping at its heels.
The genetic testing had to revise its full-year fiscal 2019 revenue guidance -- just one quarter into the fiscal year.
The genetic testing leader announced fiscal fourth-quarter 2018 earnings results and gave guidance for next year. It's the news shareholders have been waiting for.